Company intelligence / Profile preview

Advicenne

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Advicenne's lead product Sibnayal® (ADV7103, a combination of potassium citrate and potassium bicarbonate) received approval from the European Medicine Agency and MHRA in 2021 for the treatment of distal Renal Tubular Acidosis (dRTA). The product is currently in Phase III development in the United States for dRTA and is also under development for cystinuria in both Europe and the United States. The FDA has granted Orphan Drug Designation to ADV7103 for both dRTA and cystinuria in the US.

Therapeutic areas: Rare DiseasesNephrology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

Sibnayal

1 more asset in the full pipeline.

Partnerships

Avanzanite Bioscience (for commercialization in Germany, Austria, Switzerland, Greece, and other European countries)Primex Pharmaceuticals AGSPA (for marketing in Italy, Spain, and Portugal)

Beyond the preview

Go deeper on Advicenne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advicenne.